Hard Shell vs Soft Shell Hyperbaric Chamber: Complete Evidence Comparison

The hard-shell versus soft-shell hyperbaric chamber choice is decided by physics, not preference. A hard-shell (medical) chamber runs at 2.0 to 3.0 ATA with 100% oxygen and produces roughly 1,824 mmHg of arterial oxygen at 2.4 ATA. A soft-shell (mild) chamber is capped at 1.3 ATA on air or masked concentrator oxygen and produces about 230 mmHg, close to an 8x difference (Burman, 2019). Every one of the conditions the UHMS and FDA recognize for hyperbaric oxygen was studied in a hard chamber. Soft chambers are FDA-cleared for altitude sickness only.

This is not one product being slightly better than another. Hard-shell and soft-shell chambers are two device categories with different regulatory status, different oxygen delivery, and different evidence behind them. Matching the right chamber to a goal means understanding exactly what each one delivers, which is what the rest of this page lays out.

What is the real difference between hard-shell and soft-shell chambers?

A hard-shell chamber is a rigid pressure vessel that reaches 2.0 to 3.0 ATA and fills with 100% medical oxygen. A soft-shell chamber is a fabric enclosure capped near 1.3 ATA, usually on ambient air. The gap in pressure and oxygen source is what separates clinical hyperbaric oxygen therapy from mild pressurization (Burman, 2019).

Soft chambers are limited by their fabric construction to roughly 1.3 ATA. Most run on ambient room air (about 21% oxygen) compressed to that pressure. Even paired with a concentrator delivering 90 to 95% oxygen by mask, the effective oxygen dose stays far below clinical thresholds. Burman’s 2019 analysis in the South African Medical Journal put it plainly: a mild exposure on air delivers no more oxygen to the body than breathing oxygen through a mask at sea level, and exposure below 2.0 ATA on air does not meet the working definition of therapeutic hyperbaric oxygen therapy. The therapy-level distinction is covered in our mild versus clinical HBOT comparison.

Hard chambers use rigid steel, aluminum, or thick acrylic to reach 2.0 to 3.0 ATA. Monoplace units fill entirely with 100% oxygen; multiplace units pressurize with air while patients breathe oxygen by mask or hood. A 2024 study by Sack and colleagues in Undersea and Hyperbaric Medicine measured tissue oxygen directly in 130 chronic ulcer patients and found transcutaneous oxygen averaged 161 mmHg at 1.4 ATA versus 333 mmHg at 2.0 ATA, more than double (p<0.001). The gap between chamber types is even larger, because a soft chamber sits below 1.4 ATA and runs on air rather than oxygen. For the two hard-chamber subtypes, see our multiplace chamber guide.

How much more oxygen does a hard chamber actually deliver?

Oxygen dissolves into blood plasma in direct proportion to its partial pressure, following Henry’s Law (Thom, 2011; Gill and Bell, 2004). A hard chamber raises both the pressure and the oxygen fraction, so it multiplies dissolved oxygen many times over. A soft chamber raises only pressure, and only slightly, which is why its arterial oxygen barely moves above what a sea-level oxygen mask provides.

The pattern is clear. Adding pressure alone (the soft chamber) barely doubles arterial oxygen. Adding 100% oxygen at clinical pressure (the hard chamber) multiplies it roughly 15 to 18 times over baseline. Tissue oxygen tracks the same way: Sack’s 2024 oximetry data showed even 1.4 ATA on oxygen delivered only half the tissue oxygen of 2.0 ATA, and a soft chamber sits below that on air. For a deeper walkthrough of the numbers, see our soft versus hard chamber clinical data breakdown and the 2.0 ATA chamber explainer.

Which conditions is each chamber type evidenced for?

Hard chambers carry the entire recognized evidence base for hyperbaric oxygen therapy. The UHMS lists 14 approved indications and the European Committee for Hyperbaric Medicine maintains a parallel list, all built on trials run at 2.0 ATA or higher in hard chambers (Mathieu, 2017). Soft chambers have published evidence for one use only: acute mountain sickness.

The table makes the split visible. Wherever hyperbaric oxygen has earned an indication, the pressure came from a hard chamber. The soft-chamber rows carry either a single narrow clearance or no controlled evidence at all. For the formal list, see our guide to FDA-cleared HBOT indications.

Is there real clinical evidence for soft-shell chambers?

No randomized controlled trial has compared a soft-shell chamber to a hard-shell chamber for any medical condition, and no RCT has shown a soft chamber at 1.3 ATA producing the outcomes attributed to clinical HBOT. The published evidence base for soft chambers is limited to altitude sickness and small, uncontrolled reports (Burman, 2019).

Where soft-chamber pressures do appear in neurological research, they sit at the bottom of a dose-response curve. Harch’s 2022 systematic review in Frontiers in Neurology analyzed hyperbaric dosing in persistent post-concussion syndrome and found the strongest, Level 1 evidence at 1.5 ATA with 100% oxygen across four randomized trials. At 1.3 ATA on air, results were mixed (one positive study), and at 1.2 ATA on air they were split. Harch’s conclusion was that pressure within a narrow therapeutic window matters more than raw oxygen dose, which is precisely the window a 1.3 ATA air chamber fails to reach. Boussi-Gross and colleagues (2013) likewise produced their post-concussion improvements in a hard chamber, not a fabric one. The overselling of soft chambers for brain conditions is examined in detail in our piece on soft chambers oversold for neurological conditions.

This does not make soft chambers worthless. At 1.3 ATA they deliver a modest, real increase in plasma oxygen, and many home users report better sleep and recovery. What the evidence does not support is treating a 1.3 ATA air exposure as equivalent to the 2.0 ATA oxygen protocols the clinical trials actually used. See our mild hyperbaric chamber overview and soft chamber guide for realistic use cases.

Why can’t a soft chamber treat infections or wounds?

Oxygen fights infection only when tissue oxygen tension climbs high enough to power neutrophil oxidative killing and to directly suppress anaerobic and microaerophilic organisms (Knighton, 1984; Park, 1992). That level is reached at the tissue oxygen tensions produced above roughly 1.5 ATA on 100% oxygen. A soft chamber at 1.3 ATA on air never approaches it.

Knighton, Halliday, and Hunt showed in 1984 that raising inspired oxygen sharply reduced the size and number of necrotic lesions from bacterial injection in tissue, establishing oxygen tension as a direct determinant of infection resistance. Park’s 1992 review in Clinical Infectious Diseases mapped the mechanisms: elevated oxygen restores leukocyte oxidative killing and drives reactive oxygen species that damage bacterial DNA and membranes. Burman’s 2019 analysis is blunt about the threshold, holding that exposure below 2.0 ATA on air does not meet the definition of therapeutic hyperbaric oxygen. This is why infected wounds, gas gangrene, and necrotizing soft-tissue infections are treated exclusively in hard chambers, and why the Cochrane review of hyperbaric oxygen for chronic wounds (Kranke, 2015) drew entirely on hard-chamber trials. Soft chambers have no role in wound healing for infected tissue.

What does FDA clearance actually mean for each type?

Hard-shell clinical chambers are FDA-regulated Class II devices used for the recognized hyperbaric indications. Soft-shell bag chambers are FDA-cleared only to treat acute mountain sickness, and only without supplemental oxygen. No chamber is “FDA approved” for wellness or off-label conditions; clearance confirms the device is safe to market, not that a given use works (FDA).

The FDA consumer update Hyperbaric Oxygen Therapy: Get the Facts states directly that the large zippered bag chambers are cleared to treat altitude sickness only, are not cleared for use with oxygen tanks or concentrators, and that HBOT devices are not proven to treat cancer, Lyme disease, autism, or Alzheimer’s disease. The UHMS has issued a formal consumer warning about soft-sided bag chambers, stating they do not meet clinical HBOT standards. Regulatory clearance for a soft chamber therefore says nothing about efficacy for any condition beyond altitude sickness. The practical cost and clinic-access picture is in our hyperbaric chamber cost guide.

How do cost, safety, and fire risk compare?

Hard-shell clinical chambers cost $50,000 to $150,000 or more and carry a low but real fire risk that requires trained operators and formal protocols. Soft-shell chambers cost roughly $4,000 to $15,000, are portable, and have very low fire risk because they do not use a concentrated oxygen atmosphere. Both are safe when used as intended; the hazards differ by design (Sheffield and Desautels, 1997; Heyboer, 2017).

On safety, the hyperbaric record is strong. Sheffield and Desautels catalogued every reported chamber fire across 73 years and found them rare and almost always tied to ignition sources or oxygen-enriched conditions that modern protocols now control. Heyboer’s 2017 review in Advances in Wound Care quantified HBOT side effects as generally mild and reversible (ear barotrauma is the most common), and Camporesi’s 2014 review reached the same conclusion. A 2024 UHMS survey by Laspro and colleagues found practitioners overwhelmingly use 2.0 to 2.4 ATA, with 2.4 ATA the single most common pressure, underscoring that clinical HBOT lives well above the soft-chamber ceiling. Home-purchase options are compared in our best home chamber guide and portable chamber overview.

When should you choose a hard or soft chamber?

Choose a hard-shell chamber for any recognized medical indication or any goal that requires clinical-grade oxygen: wound healing, radiation injury, carbon monoxide poisoning, serious infection, or the off-label neurological protocols studied at 1.5 to 2.0 ATA. Choose a soft-shell chamber only for mild home wellness use, with the clear understanding that 1.3 ATA on air is not clinical HBOT (Burman, 2019).

If a specific condition with published evidence is the goal, that evidence was generated in a hard chamber, and matching it means matching the pressure. Long COVID is a good example: the only positive sham-controlled trial used 40 sessions at 2.0 ATA in a hard chamber, as detailed in our HBOT long COVID clinical data review. If the goal is general recovery, relaxation, or athletic maintenance, a soft chamber is a reasonable and far cheaper option, provided expectations match what 1.3 ATA can actually deliver.

Frequently asked questions